These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 37035870)
1. The efficacy and safety of nanoparticle albumin bound-paclitaxel-based regimen as second- or third-line treatment in patients with advanced esophageal squamous cell carcinoma. Xin D; Song Y; Mu L; Zhang B; Qi L; Gao J; Wang X; Xu J; Qu T; Huang J Thorac Cancer; 2023 May; 14(15):1392-1397. PubMed ID: 37035870 [TBL] [Abstract][Full Text] [Related]
2. Nanoparticle albumin-bound paclitaxel in elder patients with advanced squamous non-small-cell lung cancer: A retrospective study. Liu Y; Dong Y; Zhu H; Jing W; Guo H; Yu J Cancer Med; 2020 Feb; 9(4):1365-1373. PubMed ID: 31876976 [TBL] [Abstract][Full Text] [Related]
3. Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial. Zhang G; Yuan J; Pan C; Xu Q; Cui X; Zhang J; Liu M; Song Z; Wu L; Wu D; Luo H; Hu Y; Jiao S; Yang B EBioMedicine; 2023 Apr; 90():104515. PubMed ID: 36921563 [TBL] [Abstract][Full Text] [Related]
4. Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial. Spigel DR; Jotte RM; Aix SP; Gressot L; Morgensztern D; McCleod M; Socinski MA; Daniel D; Juan-Vidal O; Mileham KF; West H; Page R; Reinmuth N; Knoble J; Chen T; Bhore R; Wolfsteiner M; Ong TJ; Gridelli C; Thomas M; Clin Lung Cancer; 2021 Jan; 22(1):6-15.e4. PubMed ID: 33097414 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy after immune checkpoint inhibitor administration for advanced non-small cell lung cancer: A multicenter Phase 2 clinical trial. Sonoda T; Umeda Y; Demura Y; Tada T; Nakashima K; Anzai M; Yamaguchi M; Shimada A; Ohi M; Honjo C; Waseda Y; Akai M; Ishizuka T Cancer Med; 2023 Jun; 12(12):13041-13053. PubMed ID: 37081729 [TBL] [Abstract][Full Text] [Related]
6. The efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel after cisplatin plus pemetrexed in non-squamous non-small-cell lung cancer patients. Tanaka M; Hattori Y; Ishii T; Tohnai R; Itoh S; Kawa Y; Kono Y; Urata Y; Satouchi M Respir Investig; 2020 Jul; 58(4):269-274. PubMed ID: 32111518 [TBL] [Abstract][Full Text] [Related]
7. Phase I study of cisplatin and nanoparticle albumin-bound-paclitaxel combined with concurrent radiotherapy in locally advanced esophageal squamous cell carcinoma. Jiang H; Li Q; Chen B; Xi M; Makelike K; Liu S; Hu Y; Zhu Y Cancer Med; 2023 Jul; 12(14):15187-15198. PubMed ID: 37334881 [TBL] [Abstract][Full Text] [Related]
8. Weekly nanoparticle albumin-bound paclitaxel in combination with cisplatin versus weekly solvent-based paclitaxel plus cisplatin as first-line therapy in Chinese patients with advanced esophageal squamous cell carcinoma. Wang HY; Yao ZH; Tang H; Zhao Y; Zhang XS; Yao SN; Yang SJ; Liu YY Onco Targets Ther; 2016; 9():5663-5669. PubMed ID: 27713635 [TBL] [Abstract][Full Text] [Related]
9. ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC). Morgensztern D; Cobo M; Ponce Aix S; Postmus PE; Lewanski CR; Bennouna J; Fischer JR; Juan-Vidal O; Stewart DJ; Fasola G; Ardizzoni A; Bhore R; Wolfsteiner M; Talbot DC; Jin Ong T; Govindan R; On Behalf Of The Abound L Investigators Cancer; 2018 Dec; 124(24):4667-4675. PubMed ID: 30383906 [TBL] [Abstract][Full Text] [Related]
10. Clinical Efficacy of Taxol Plus Platinum (TP) Chemotherapy Combined with Delayed Administration of PD-1 Inhibitors in Patients with Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma: A Retrospective Study. Shen L; Chen Z; Zhang Z; Wu Y; Ren Y; Li Y; Li Y; Yin X; Han F; Chen Y Drug Des Devel Ther; 2024; 18():2761-2773. PubMed ID: 38979399 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Nab-Paclitaxel as Second-line Chemotherapy for Locally Advanced and Metastatic Non-small Cell Lung Cancer. Gong W; Sun P; Mu Z; Liu J; Yu C; Liu A Anticancer Res; 2017 Aug; 37(8):4687-4691. PubMed ID: 28739772 [TBL] [Abstract][Full Text] [Related]
12. Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma. Fan Y; Jiang Y; Zhou X; Chen Q; Huang Z; Xu Y; Gong L; Yu H; Yang H; Liu J; Lei T; Zhao Q; Mao W Oncotarget; 2016 Aug; 7(31):50624-50634. PubMed ID: 27244882 [TBL] [Abstract][Full Text] [Related]
13. Retrospective analysis of the effectiveness and tolerability of nab-paclitaxel in Chinese elderly patients with advanced non-small-cell lung carcinoma. Wang S; Liang Q; Chi Y; Zhuo M; An T; Duan J; Wang Z; Wang Y; Zhong J; Yang X; Chen H; Wang J; Zhao J Thorac Cancer; 2020 May; 11(5):1149-1159. PubMed ID: 32162417 [TBL] [Abstract][Full Text] [Related]
14. A phase II study of nanoparticle albumin-bound paclitaxel plus carboplatin as the first-line therapy in elderly patients with previously untreated advanced non-small cell lung cancer. Okuma Y; Hosomi Y; Takahashi S; Nakahara Y; Watanabe K; Nagamata M; Takagi Y; Mikura S Cancer Chemother Pharmacol; 2016 Aug; 78(2):383-8. PubMed ID: 27339149 [TBL] [Abstract][Full Text] [Related]
15. A single-arm phase II trial of weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) monotherapy after standard of chemotherapy for previously treated advanced non-small cell lung cancer. Kato Y; Okuma Y; Watanabe K; Yomota M; Kawai S; Hosomi Y; Okamura T Cancer Chemother Pharmacol; 2019 Aug; 84(2):351-358. PubMed ID: 30993397 [TBL] [Abstract][Full Text] [Related]
16. Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial. Lu M; Wang X; Shen L; Jia J; Gong J; Li J; Li J; Li Y; Zhang X; Lu Z; Zhou J; Zhang X Cancer Sci; 2016 Apr; 107(4):486-90. PubMed ID: 26797530 [TBL] [Abstract][Full Text] [Related]
17. Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. Luo H; Lu J; Bai Y; Mao T; Wang J; Fan Q; Zhang Y; Zhao K; Chen Z; Gao S; Li J; Fu Z; Gu K; Liu Z; Wu L; Zhang X; Feng J; Niu Z; Ba Y; Zhang H; Liu Y; Zhang L; Min X; Huang J; Cheng Y; Wang D; Shen Y; Yang Q; Zou J; Xu RH; JAMA; 2021 Sep; 326(10):916-925. PubMed ID: 34519801 [TBL] [Abstract][Full Text] [Related]
18. The Safety and Efficacy of Treatment with Nab-paclitaxel and Carboplatin for Patients with Advanced Squamous Non-small Cell Lung Cancer Concurrent with Idiopathic Interstitial Pneumonias. Fujita T; Hiroishi T; Shikano K; Yanagisawa A; Hayama N; Amano H; Nakamura M; Hirano S; Tabeta H; Nakamura S Intern Med; 2018 Jul; 57(13):1827-1832. PubMed ID: 29434143 [TBL] [Abstract][Full Text] [Related]
19. Clinical investigation of efficacy of albumin bound paclitaxel plus platinum compounds as first-line chemotherapy for stage III/IV squamous non-small cell lung cancer. Fang Y; Wang L; Xia GH; Shi MQ Asian Pac J Cancer Prev; 2014; 15(17):7453-7. PubMed ID: 25227858 [TBL] [Abstract][Full Text] [Related]
20. Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and Pemetrexed. Ciunci CA; Reibel JB; Evans TL; Mick R; Bauml JM; Aggarwal C; Marmarelis ME; Singh AP; D'Avella C; Cohen RB; Langer CJ Clin Lung Cancer; 2022 Jun; 23(4):e310-e316. PubMed ID: 35393247 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]